MIR-155-5P inhibitor

1. MIR-155-5P inhibitor decreases osteoarthritis in mice.

   “intra-articular injection of miR-155-5p inhibitor or recombinant GDF6 could significantly mitigate the severity of impending OA and lessened the progression of existing OA.”

   Animalsin murine overloading-induced OA models

   The PIEZO1/miR-155-5p/GDF6/SMAD2/3 signaling axis is involved in inducing the occurrence and progression of osteoarthritis under excessive mechanical stress

   Cellular signalling·18 Mar 2024

More on Osteoarthritis

1. MIR-155-5P inhibitor increases lipid and ceramide metabolism in mouse cells.

   “enhanced lipolysis (indicated by increased ATGL and p-HSL) in senescent hepatocytes.”

   Cellssenescent hepatocytes

   miR-155-5p promotes hepatic steatosis via PICALM-mediated autophagy in aging hepatocytes

   Archives of gerontology and geriatrics·9 Jan 2024

More on Lipid and ceramide metabolism

1. MIR-155-5P inhibitor increases autophagy in mouse cells.

   “Inhibition of miR-155-5p reduced expression of senescent marker genes (p16, p21, p-P53), improved autophagy (evidenced by increased LC3B-II and ATG5, and decreased P62)”

   Cellssenescent hepatocytes

   miR-155-5p promotes hepatic steatosis via PICALM-mediated autophagy in aging hepatocytes

   Archives of gerontology and geriatrics·9 Jan 2024

More on Autophagy

1. MIR-155-5P inhibitor decreases lipid accumulation in mouse cells.

   “Oil red O staining confirmed that miR-155-5p inhibition significantly reduced lipid accumulation in these cells.”

   Cellssenescent hepatocytes

   miR-155-5p promotes hepatic steatosis via PICALM-mediated autophagy in aging hepatocytes

   Archives of gerontology and geriatrics·9 Jan 2024